Lavender Hill Capital's Healthcare Portfolio Bears Fruit as RiboBio Ushers in a New Era of Global Expansion for China's Small Nucleic Acid Therapeutics

Ribo Life Science, founded in 2007, is an innovative biopharmaceutical company dedicated to the research and development of small nucleic acid drugs, with a particular focus on siRNA therapies. The company is one of the very few enterprises globally that owns a self-developed and clinically validated GalNAc delivery technology as well as its proprietary RiboGalSTAR™ liver-targeting delivery platform. It has established a comprehensive self-developed technological platform system covering the entire process of small nucleic acid drug development, achieving an "end-to-end" capability loop from early-stage research, CMC (Chemistry, Manufacturing, and Control), to clinical development and future commercialization. Currently, the company has grown into a benchmark enterprise in China’s small nucleic acid drug field and has become a key player in this global technology track.

Ribo Life Science boasts strong R&D capabilities and an international perspective. The company has established R&D centers or clinical trial bases in Suzhou and Beijing, China, as well as in Malmö, Sweden, forming an international team of 272 R&D personnel. Through independent innovation, Ribo Life Science has applied for 473 patents, covering more than 20 countries and regions worldwide. It has also entered into deep collaborations with international pharmaceutical giants such as Boehringer Ingelheim and Qilu Pharmaceutical, promoting the global clinical development and commercialization of candidate drugs. This has built a solid barrier for the long-term development of its core products and pipeline candidates.

Small nucleic acid drugs, as the next generation of biotechnology, are reshaping the global pharmaceutical industry landscape with their precise targeting and long-term regulation advantages. According to Frost & Sullivan forecasts, by 2034, the global small nucleic acid drug market size will exceed $54.9 billion. Ribo Life Science, with its deep technical accumulation and forward-looking layout, is expected to achieve breakthroughs in billion-dollar treatment areas such as cardiovascular diseases and liver diseases, providing safer and more effective treatment options for patients worldwide.

Legend Capital invested in Ribo Life Science multiple times in 2015, 2016, 2017, 2019, 2020, and 2022. After the investment, Legend Capital fully leveraged its deep expertise in the healthcare sector and the advantages of its medical ecosystem network to provide continuous value-added services in corporate strategy development, talent acquisition, and international expansion, helping the company steadily advance its R&D pipeline and move towards its IPO process.

Legend Capital stated: The successful listing of Ribo Life Science marks a milestone achievement after more than a decade of unwavering commitment to original innovation and deep cultivation in the golden track of small nucleic acids. With a fully independent delivery platform and technology system, the company has not only successfully developed a differentiated pipeline with global competitiveness but also targeted unmet clinical needs in major disease areas such as cardiovascular and metabolic diseases, demonstrating tremendous potential to become a world-leading biopharmaceutical company. We look forward to the company taking its listing as a new starting point to further accelerate the clinical research and commercialization layout of its core products, bringing more breakthrough therapies to patients worldwide while injecting strong momentum into the innovative upgrading of China's biopharmaceutical industry.

Legend Capital has consistently made systematic investments in the innovative drug sector, adhering to the investment philosophy of "global perspective, China focus." They seek out technologies and teams with genuine international competitiveness to address unmet clinical needs.